Skip to content

An exploratory study to evaluate the effect of a new study product on early programming in healthy infants

An exploratory study to evaluate the effect of a new study product on early programming in healthy infants - EAGLE2

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34471
Enrollment
28
Registered
2011-01-17
Start date
2011-02-11
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects digestion and absorption

Interventions

7 week feed with the new IMF or the control IMF

Sponsors

Danone Vitapole
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: Healthy and full-term infants (gestational age * 37 and * 42 weeks) Birth weight within the normal range for gestational age and sex (10th to 90th percentiles according to applicable growth charts) Age * 7 weeks at screening Body weight appropriate for the individual age and sex at screening (10th to 90th percentiles according to applicable growth charts) Infants who are fully formula fed or have started the transition from breast- to formula-feeding (indicated by the feeding of at least one bottle of infant formula in the past) and are planning to stop breastfeeding voluntarily by infant*s age of 7 weeks Written informed consent of both parent(s)/legal guardian(s)

Exclusion criteria

Exclusion criteria: Infants not on full formula feeding at the age of 7 weeks (to be answered latest at the age of 8 weeks (visit 2)) Infants with known congenital diseases or malfunctions e.g. gastrointestinal malformations, haemophilia Current or previous illnesses which could interfere with the study (e.g. prolonged severe diarrhoea, regurgitation) *Infants with abnormal growth (too slow ( +1SD) weight gain) within the 10th to 90th percentiles of applicable weight-for-age charts for either boys or girls Infants at high risk to develop an atopic disease (at least one parent or sibling with manifest atopic symptoms of hay fever, asthma or atopic dermatitis) Infants needing a special diet other than standard cow*s milk-based infant milk formula *Infants whose mothers are known to suffer from hepatitis B, human immunodeficiency virus (HIV), high blood-pressure, hyperlipidaemia or diabetes Infants whose mother was overweight (BMI * 27) prior to pregnancy Infants with any historical or current participation in any other study involving investigational or marketed products Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements and instructions

Design outcomes

Primary

MeasureTime frame
Absorption and digestion of feed components.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)